Test Price
2,800 AED✅ Home Collection Available
ZFYVE27 Gene SPG33 Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين ZFYVE27 SPG33 الوراثي بتقنية التسلسل الجيني المتقدم في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary / الخلاصة التنفيذية
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing.
- Premium Logistics: Hospital-Grade Home Collection by ISO-Certified Cold-Chain Phlebotomy Team.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in Result Interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
تحليل معتمد هيئة الصحة بدبي، بدقة 99.9% واستشارة هاتفية ما بعد الفحص، مع خدمة السحب المنزلي المتميزة.
Pre-Test Requirement: A genetic counselling session to draw a pedigree chart of family members affected with ZFYVE27 Gene SPG33 is mandatory. Please call to schedule.
Overview of ZFYVE27 Gene SPG33 Genetic Test
This advanced next-generation sequencing test analyzes the entire ZFYVE27 gene to identify pathogenic variants causing Hereditary Spastic Paraplegia type 33 (SPG33), a progressive neurological disorder. يقوم هذا الفحص بتحليل الجين المسؤول عن الشلل النصفي التشنجي الوراثي type 33.
| Feature | Our Test (NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | >99.9% analytical sensitivity | Variable, may miss deep intronic variants |
| Method | Full-gene NGS (all exons + splice sites) | Select exon amplification |
| Turnaround Time | 3 to 4 weeks | 6 to 8 weeks |
Specimen accepted: Blood, Extracted DNA, or One Drop Blood on FTA Card.
Primary diagnosis and management of hereditary spastic paraplegia SPG33; long-term follow-up of motor symptoms.
Post-test variant interpretation, recurrence risk counseling, and family pedigree evaluation.
Early-onset SPG33 in minors; developmental assessment and coordination of care under CDS Law 2026.
Physician Insight & Safety Protocol
From Dr. Prabhakar Reddy, DHA-61713011, Consultant Neurologist: “A positive ZFYVE27 result can clarify a long diagnostic journey, yet each variant must be weighed against your personal clinical picture. Genetic findings are a compass, not the entire map—interpretation alongside a neurologist is essential to guide treatment and family planning.”
“Please remember correlation with clinical findings remains paramount; a negative genetic test does not exclude all forms of spastic paraplegia. Trust the process and continue your clinical follow-up.”
⚠️ Medication Safety: Do Not Discontinue Prescribed Medication Without Consulting Your Doctor
Never alter, stop, or adjust your anti-spastic, neuroprotective, or any other prescribed therapy based solely on genetic results. Abrupt changes can lead to rebound spasticity, falls, or other serious events.
🚨 Exclusion Criteria & Emergency Red Flags
- Exclusion: Recent allogeneic bone marrow or hematopoietic stem cell transplant (chimerism risk); active hematologic malignancy with circulating blasts.
- Exclusion: Unwillingness to provide complete three-generation pedigree during genetic counselling session.
- ER Red Flags: Sudden paralysis of any limb, acute visual loss, or new-onset seizures require immediate emergency department visit regardless of test status.
- ER Red Flags: Severe aspiration or breathing difficulty – call 998.
Legal & Regulatory Compliance
Federal Decree-Law No. 41 of 2024 (Art. 87): This genetic test adheres to mandated quality controls and reporting standards for hereditary neurological conditions.
CDS Law 2026 (Minors): For individuals under 18, testing requires parental consent and post-test genetic counselling tailored to pediatric care.
UAE PDPL: All patient data are encrypted and processed in compliance with the Personal Data Protection Law; genetic information is classified as sensitive personal data.
ISO 9001:2015 Certified Facility (Cert: INT/EGQ/2509DA/3139) | Facility License: 9834453
Patient FAQ & Clinical Guidance
Q: What is the purpose of testing the ZFYVE27 gene, and who should consider it?
A: It identifies pathogenic variants causing SPG33 to confirm a clinical diagnosis and guide personalized management. This test detects disease-causing mutations in the ZFYVE27 gene responsible for hereditary spastic paraplegia type 33.
س: ما الهدف من تحليل جين ZFYVE27 ومن ينبغي أن يخضع له؟
ج: يكشف الطفرات الممرضة في الجين لتأكيد التشخيص السريري للشلل النصفي التشنجي الوراثي type 33 وتوجيه العلاج.
Q: How is the sample collected and is it painful?
A: A small blood draw from the arm or a finger prick onto an FTA card, causing minimal discomfort. Our certified phlebotomist uses a virtually painless technique for sample collection at your home.
س: كيف يتم جمع العينة وهل الإجراء مؤلم؟
ج: يتم سحب عينة دم صغيرة من الوريد أو وخز الإصبع على بطاقة FTA، مع شعور بسيط جداً بعدم الراحة.
Q: How long until I receive my results and what happens next?
A: Results are ready in 3 to 4 weeks, followed by a teleconsultation with our neurologist to explain findings. Your comprehensive report will be reviewed with you within 3 to 4 weeks via a dedicated clinical guidance call.
س: متى أحصل على النتائج وماذا بعد ذلك؟
ج: تكون النتائج جاهزة خلال 3 إلى 4 أسابيع، يليها استشارة هاتفية مع طبيب الأعصاب لشرحها.
To order this or verify insurance:
WhatsApp Support: +971 54 548 8731 (8 AM – 11 PM daily)
DHA Licensed, ISO 9001:2015 Certified. Your genetic data privacy is protected under UAE law.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians